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ABSTRACT Fundamental to the analysis of protein polymerization is the free energy of association, typically determined from
solubility. It has been previously shown that concentrated 70 kDa dextran lowers the solubility of sickle hemoglobin, due to
molecular crowding, and provides a useful ranking tool for the effects of inhibitors and molecular modiﬁcations. Because
hemoglobin occupies a substantial volume as well, crowding effects of both hemoglobin and dextran contribute to the nonideality
of the solution. We show how scaled-particle theory can be used to account for both types of crowding, thus allowing the
determination of solubility in the absence of dextran, given data measured in its presence. The approach adopted approximates
dextran as a sphere with a volume that decreases as the concentration of dextran increases. We use an asymptotic relation to
describe the volume, which decreases nearly linearly by a factor of two over the range studied, from 60 to 230 mg/ml. This
compression is similar to previously observed compression of sephadex beads and ﬁcoll solutions. In the limit of low hemoglobin
concentrations, the theory reduces to the previously-used approach of Ogston. Our method therefore provides a means of
measuring the free energy of association of molecules that occupy signiﬁcant volume fractions, even when assisted by the
crowding of dextran and we present a tabulation of all known free energies of polymerization of sickle hemoglobinmeasured in the
presence of dextran.
INTRODUCTION
The pathology of a number of diseases, of which perhaps the
most prominent members are Alzheimer’s and Mad Cow
disease, is related to protein assembly into large, fibrous struc-
tures. Fundamental to understanding protein assembly dis-
eases is a measure of the interaction of the molecules within
the aggregate, and the free energy of interest can be learned
from the measurement of solubility. The formation of aggre-
gates may also occur in crowded environments (1), a finding
that has inspired the study of assembly in the presence of
crowding agents such as high-molecular-weight dextran.
Moreover, it is possible by adjustment of crowding condi-
tions to promote aggregation (2–4) and thus induce aggre-
gation under conditions that might otherwise not be amenable
to protein association. Although crowding may be a natural
part of some processes, a molecular understanding requires
that energetics of the assembled polymer or fibril be known
independent of the crowding process.
Sickle hemoglobin polymerization is the basis of the oldest
known assembly disease, sickle cell disease, and occurs once
the concentration of monomers exceeds a concentration var-
iously designated as csat or as solubility, cs. Under conditions
near physiological, this solubility is ;160 mg/ml (5). Inves-
tigation of the propensity to form such polymers therefore
typically requires a significant mass of hemoglobin, and, par-
ticularly if mutant proteins are to be studied, this requirement
can be difficult to achieve. Smaller amounts of protein can
be employed if the solubility is reduced by dramatically in-
creasing the ionic strength of the solution, (6,7) but such a
strategy often raises questions of whether intrinsically impor-
tant ionic interactions have been modified by the changed ionic
strength. An alternative is to adjust the protein activity by
adding inert molecules, thus crowding the solution, and al-
tering the activity coefficients that formally account for solu-
tion crowding. By using 100–120 mg/ml of 70 kDa dextran,
the HbS solubility can be reduced to 30–40 mg/ml, in striking
validation of the concept (4). The fibers produced in the
presence of the dextran are indistinguishable by electron mi-
croscopy from those found in its absence (4).
Despite the utility of the approach, as evidenced by its
widespread use (4,8–11) and the conceptual clarity of its
origin, no quantitative thermodynamic connection has been
shown between solubility measured without dextran and
solubility determined in the presence of this crowding agent.
Dextran has been used in other studies on protein association
and folding (3,12–14), and in those studies it has typically
been successfully described by a model developed by Ogston
(15). However, in Ogston’s model it is assumed that only the
dextran has significant volume crowding, and thus the theory
cannot be employed when any other species occupies a
substantial volume as well, as is the case in hemoglobin
polymerization. The absence of a successful theory for dex-
tran effects on hemoglobin polymerization is particularly
limiting if one wishes to deduce free-energy changes, in
which case activity coefficients must be known. Moreover, it
is important if experiments executed under one set of con-
ditions need to be compared to those executed under another
set. For example, a mutant Hb that might be a candidate for
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gene therapy could be assayed in the presence of dextran, but
its actual efficacy needs to be known under physiological con-
ditions. Although the dextran results provide a proper ranking
tool (showing what changes increase or decrease solubility, for
example), the thermodynamic connection is not present.
In this article, we use scaled-particle theory, a particularly
successful theory for relating hard-sphere exclusion between
spheres of any size, to account for solution crowding of
dextran and hemoglobin molecules in the same solution in
which solubility is measured. In using the hard-sphere cal-
culation it is necessary to vary the volume of the dextran
particles, depending on the final dextran concentration. This
is rationalized as the consequence of interpenetration of the
dextran.
MATERIALS AND METHODS
Hemoglobin was purified chromatographically, as described elsewhere (16).
Buffers were 0.15 M phosphate, pH 7.35. Dextran was obtained from Sigma,
and used without further preparation. Hemoglobin concentrations were ob-
tained by measuring optical absorption spectra in the Soret region (400–450
nm), and fitting the entire spectrum to known standards. For one set of ex-
periments, C-14 was used to track the composition of the supernatant.
A series of experiments was analyzed, for which results have been pre-
viously reported, in which conventional centrifugation methods were used to
separate the gel formed in dextran (4). In addition, we employed a newly
developed photolytic method (17). This procedure uses an emulsion of
COHbS in castor oil placed between microscope coverslips. A particular
droplet is selected and subjected to continuous laser photolysis except for a
small spot at the droplet center. This spot serves as a reservoir from which
monomers will be drawn into the photolyzed, polymerizing region until
solubility in the reservoir is reached. Droplets were 200–300 mm in diameter
and a few micrometers thick, and the masked area at their center is 4–5% of
the total area. The spectrum of the reservoir is measured using an Ocean
Optics (Dunedin, FL) 2000 spectrometer. Photolysis is achieved using a
Lambda-Pro green solid-state laser. The sample is observed with 153 re-
flecting microscope optics (Ealing, Holliston, MA). As shown below, the
new method gives results that agree with the conventional approach. How-
ever, the new method uses only a few microliters of sample per experiment,
can be repeated a number of times, and can readily measure solubility at a
number of different temperatures.
Theory
The central theoretical concept is that solution monomers with chemical
potential mS, are in equilibrium with a polymer phase of chemical potential
mP. This implies equality of the chemical potentials, i.e.,
mP ¼ mS: (1)
The polymers are treated in a crystal approximation (18), and thus
mP ¼ mPC1mPV; (2)
where PC denotes the contribution from molecular contacts and PV the
contribution from vibrations of the molecules in polymers, moving about
their center of mass. The solution has translational and rotational freedom,
and thus
mS ¼ mTR1RT lngScS; (3)
where S subscripts have been added, anticipating that we are considering the
solution at solubility. g is an activity coefficient that depends on concentra-
tion, and thus has an S subscript as well. We have found that for hard spheres
such as hemoglobin, a simple yet accurate expression is (19)
ln g ¼ 8f=ð1  fÞ2; (4)
where f is the volume fraction, which is given for simple hemoglobin (Hb)
solutions by the equation f ¼ VHbc.
Thus, the monomer-polymer equilibrium is described by a solubility, cS,
which satisfies the equation
ln gScS ¼ ðmPC1mPV  mTRÞ=RT: (5)
Since the righthand side of this equation does not change as the solution is
crowded, it is evident that changes in the activity coefficient are offset by
changes in solubility. If g9Sc9S represents activity in a crowded milieu, then
g9Sc9S ¼ gScS: (6)
To calculate g9S requires a specific prescription for incorporating crowding.
An effective way is scaled-particle theory, which allows similarly shaped
particles to be employed in the calculation of their mutual crowding (20). The
activity coefficient for Hb, taken as a hard sphere in the presence of dextran,
also taken as a spherical crowding agent, is denoted as gsp and is given by
Minton (20) as
ln gsp ¼ lnð1  YÞ1B
RHb
1  Y1 ð4pA1
1
2
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in which Y is the fraction of space occupied, and is given by
Y ¼ VHb½Hb1Vdex½dex; (8)
and the auxiliary constants A and B are given by
A ¼ RHb½Hb1Rdex½dex (9)
and
B ¼ 4pðR2Hb½Hb1R2dex½dexÞ; (10)
and VHb is the specific volume of Hb, with VHb ¼ ð4p=3ÞR3Hb; and similarly
for dextran. It is convenient to factor the hemoglobin volume, and to write
Vdex as multiples of VHb. Thus, we define vdex as the ratio Vdex/VHb. Because
spherical objects are assumed, once Vdex is determined, the radius, Rdex, can
be deduced. Other approaches have been used for dextran, and will be
compared in the Discussion section. For now, it is sufficient to point out that in
the other approaches that have been used, the particle crowded (e.g., Hb) was
much more dilute than the crowder. That assumption cannot be made here.
Since dextran does not go into the polymer, it is necessary to correct the
final dextran concentration in supernatant solution, which is done by simple
mass conservation according to
½dex ¼ ½dexo
1  co  cs
cpp
; (11)
in which [dex]o is the initial concentration of dextran, c0 is the initial con-
centration of Hb, and cpp is the concentration of Hb in the polymer phase,
which is the inverse of the specific volume of the polymer phase.
RESULTS AND DISCUSSION
Using Eq. 11, we computed the expected final concentration
of dextran in each sample. This was compared with the
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radiolabeled dextran which, taken from the supernatant, gives
a direct measurement. The results are shown in Table 1. As
can be seen, agreement is excellent, using cpp ¼ 55 g/dl (21).
The average difference is a mere 0.019 g/dl, ;0.1%.
To determine the appropriate specific volume for use in
Eq. 8, we first employed a volume determined by density
measurement of the dextran, which yielded 0.664 ml/g, in
good agreement with published values (22) This is equal to
0.0465 L/mmol, which is within a few percent of the specific
volume for Hb, 0.0482 L/mmol. When used in the scaled-
particle theory, this did not yield good agreement. We
therefore reversed the procedure, and determined a specific
volume that would suffice to reconcile the dextran-free sol-
ubility with that measured in various dextran concentrations.
This yielded a series of volumes that depended on the initial
dextran concentration, as shown in Fig. 1, and decreased as
dextran concentration increased. These volumes are all given
relative to the volume of Hb, and are therefore dimensionless.
To explore this behavior further, we obtained additional
data at 22C and 37C. The solubility data is shown in Table
2, along with the published data (4) for comparison. Typical
reproducibility of the solubility data was 3%, and in no case
worse than 4%. The dextran volume determined by analysis
of this data is shown in Fig. 1, and is in generally excellent
agreement with the published 22C data, while extending its
range. It is noteworthy that both temperatures give the same
effective volume.
Published data at 37C (4) was not used because the ac-
cepted protocol for this method is to gel the sample at 37C,
but to centrifuge it at room temperature. (4,8–10) This raises
the possibility that some of the gel will dissolve during
sedimentation and processing, and that the effective tem-
perature is neither 37C nor room temperature. We will return
to this issue in the discussion.
The dimensionless volume ratio data of Fig. 1 was fit by
the empirical equation
vdex ¼ vo1Dv=2ð1  tanh ðð½dex  ½dexmÞ=DcÞÞ; (12)
in which vo, Dv, [dexm] and Dc are constants determined by
fitting to the data. From the fit, it is found that vo ¼ 1.79 and
Dv¼ 2.70, and [dexm] ¼ 14.01 g/dl, and the width Dc¼ 8.75
g/dl. As can be seen in Fig. 1, the function, selected to have
high and low asymptotes, provides a good fit.
The consistency of the variable volumes used for dextran,
independent of temperature and Hb concentration suggested
that the approach had validity. Moreover, other workers have
observed the compressibility of dextran (23), as well as the
closely related Ficoll (12). Quantitatively, the size variation
FIGURE 1 Relative specific volume of dextran as a function of final
dextran concentration. Dextran volume is measured relative to the volume of
hemoglobin. Volume was determined by using Eq. 7 for the scaled-particle
activity coefficient to determine the volume that gave the solubility, as listed
in Table 2. (Open circles) 22C data published previously (4); (solid circles)
22C data determined here; (diamonds) 37C data determined here. The
curve is the best fit of the empirical function of Eq. 12.
TABLE 1 Comparison of measured and predicted
dextran concentrations
Measured [dex] (g/dl) Predicted [dex] (g/dl)
12.5 12.7
12.5 12.7
13.0 13.0
13.0 13.0
12.9 13.0
13.2 13.0
14.3 14.3
14.1 14.3
13.3 13.0
13.4 13.0
Dextran concentration was predicted based on Eq. 11.
TABLE 2 Solubilities of sickle hemoglobin with dextran
[dex]o (g/dl) [dex] (g/dl) Csat (g/dl) [Hb]o (g/dl) Temperature (C)
Measured by centrifuge
21 22.10 1.27 4 22
18 18.81 1.63 4 22
15 15.47 2.32 4 22
21 22.66 0.96 5 22
18 19.25 1.42 5 22
15 15.84 2.09 5 22
12 12.39 3.28 5 22
Measured by droplet and mask
21 21.40 0.97 2.01 22
18 18.46 1.38 2.75 22
18 18.40 1.44 2.62 22
15 15.58 2.25 4.31 22
15 15.42 2.50 3.99 22
12 12.79 3.37 6.77 22
12 12.63 3.41 6.17 22
10 10.27 4.75 6.17 22
8 8.87 6.08 11.45 22
6 6.25 9.10 11.34 22
18 19.69 0.78 5.49 37
15 16.39 1.50 6.16 37
12 13.11 2.10 6.77 37
10 10.47 3.70 6.17 37
6 6.45 7.50 11.34 37
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of dextran volume appears reasonable. This can be seen by
considering the asymptotic values of the empirical function
(Eq. 12). As described above, the volume of the hemoglobin,
insofar as it excludes water, is the same as 70 kDa dextran, so
we expected the volume of dextran (per mmol) to be at least
as great as that of Hb. Thus, it is likely that the ratio vdex. 1.
At the high [dex] asymptote, vdex/vo ¼ 1:79: The low [dex]
asymptote corresponds to highly dilute conditions, where a
number of investigators have measured the effective hydro-
dynamic radius of dextran (treating it as a sphere). Typical
results are 6.49 nm (24), 6.39 nm (25), and 6.2 nm (26). For
Hb, the radius is 3.2 nm (27). Thus, from hydrodynamics,
one would expect the maximum vdex to be;(6.35/3.2)
3 ¼ 8.
At the low [dex] asymptote (i.e., 0), we find vdex/4:39:
Hence, the asymptotes of the function employed appear well
within the bounds of what is known about dextran.
The variation of volume is rationalized by the observation
that dextran is not a densely packed object, since its hydration
volume is similar to that of Hb whereas its hydrodynamic
volume is eight times that of Hb. At the highest concentra-
tions used here (21 g/dl), dextran of specific volume eight
times that of Hb would overfill the available volume, i.e.,
overlapping would be required to allow it to fit. If we take the
well known filling factor of hard spheres of 0.74, and assume
the dextran to be hard spheres with 8Hb volume, the solution
is completely packed at 12 g/dl. In other words, at concen-
trations of 12 g/dl and above, the dextran must overlap. For
concentrations from 6 g/dl to 12 g/dl, though space filling
considerations don’t require overlap, it is evident that some
overlap must occur by the random encounter of the dextrans.
Fig. 2 illustrates the effect this has on excluded volume. As
the concentration of dextran rises, even though the number of
dextran molecules encountered by a Hb molecule rises, each
dextran denies less effective volume to the Hb thanks to their
overlap.
The empirical function of Eq. 12 contains asymptotes that
are limited, but not specified, by external data. Consequently,
it is possible to imagine a different function that might have
different asymptotes. The data itself are close to linear, and a
linear fit is quite acceptable. However, the asymptotic form
provides a better fit even when the effects of the extra pa-
rameter are taken into account. Specifically, the sum of the
squared deviations divided by the degrees of freedom
(number of data points minus number of parameters minus
number of equations) is 5.33 103 (g/dl)2 for the asymptotic
fit and 7.5 3 103 (g/dl)2 for the linear fit.
Unlike proteins, dextrans exhibit polydispersity of molecular
weight (28–30). The dextran used here did not have a range
FIGURE 2 Schematic of dextran overlap. The picture illustrates dextran
with a hydrodynamic radius twice that of Hb, in agreement with measure-
ments, surrounding Hb. Dextran is drawn schematically, and, unlike Hb, is not
a compact object. As the concentration increases, the dextrans surrounding Hb
each exclude less volume because of their overlap. Though only one Hb is
shown, the neighboring Hb molecules will be roughly one dextran diameter
away.
FIGURE 3 Activity coefficient g, as a function of dextran concentration,
for trace concentrations of Hb. The theory of Ogston (15) (Eq. 13) is rep-
resented by the straight line, whereas the scaled-particle theory, employed
here, is represented by the dashed undulating curve. Dotted lines show the
theoretical curve in regions where volume data (Fig 1) was not collected, but
which depend on the empirical function.
FIGURE 4 Correlation of predicted and measured solubility. (Left) The
data gelled at 37C and measured at 22C are shown as solid triangles, using
the assumption that the correct temperature is the gelation temperature,
37C. As can be seen, the points are not so well correlated as the other data.
(Right) The correlation resulting when the appropriate temperature is taken
to be 25C. Light gray symbols represent the data from Table 2. (Open
circles) 22C data published previously (4); (solid circles) 22C data
determined here; (diamonds) 37C data determined here.
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specified by the manufacturer, but similar products have a dis-
tribution width of ;10% of the mean (e.g., Pharmacosmos
Dextran Standards, Pharmacosmos, Holbaek, Denmark.) We
examined the results of using a mixture of two equal con-
centrations of dextran at the upper and lower standard devi-
ations, i.e., 63 kDa and 77 kDa. There was no significant
change in ln g by using this extremely bimodal distribution,
and thus we conclude that polydispersity does not have a
significant effect on the approach taken here.
The approach using scaled-particle theory differs from that
of Ogston (15), subsequently employed by others (e.g., (14))
in the analysis of dextran’s influence on protein behavior.
Ogston’s approach involved considering dextran as an as-
semblage of polymeric rods of radius a (rod length does not
enter into the formalism). The rods exclude a spherical par-
ticle, in this description, of radius r. If the dextran occupies a
volume fraction fd (¼ Vdex[dex]), then
ln g ¼ ð11 r=aÞ2fd: (13)
Minton (31) has used a¼ 0.7 nm for dextran, and r¼ 3.2 nm
for Hb (27). We can compare the result of our analysis with
scaled-particle theory in the limit where the concentration of
Hb is small, and this is shown in Fig. 3. The agreement is
excellent, validating further the variable volume approach. It
is also interesting to note that the Ogston approach is
specifically immune to issues of overlap of the dextran
particles.
With the accuracy of the method established, it is inter-
esting to return to the data of Bookchin et al. (4) collected at
37C gelation with room temperature (22C) centrifugation,
which we shall label 37() data for convenience. Fig. 4
shows a correlation of the solubility computed using Eq. 1 of
Li et al. (32), the volume function of Eq. 12, and measured
solubility. In the left panel, the 37() data is used as if the
temperature were continuously held at 37C. As can be seen,
this data, while close, fails to correlate as well as the other
points. If, however, we adjust the temperature (which adjusts
the solubility used in Eq. 6), we find a good correlation for an
apparent temperature of 25C, as seen in the right panel of
Fig. 4. Because this apparent temperature is likely to depend
on procedural details, it is uncertain how universally appli-
cable this particular finding is, and it would be far more
useful, in future analysis of HbS solubility, to centrifuge and
gel at a single temperature. In such future reports, it would
also be important to tabulate the initial Hb concentration of
samples, so as to allow accurate determination of the final
dextran concentration from Eq. 11.
Finally, in Table 3, we have tabulated the calculated dex-
tran-free solubilities and the free energies of association for
all the mutant hemoglobins that have been studied by the
dextran method to date. We can compare our predicted sol-
ubilities for two cases in which solubilities without dextran
had also been determined (33,34). Those experiments used
the Benesch method, which assigns solubility to the con-
centration at which there is a change in the slope of p50
plotted as a function of concentration (35). The values shown
in Table 3 are somewhat below those inferred in the original
publications, but would actually be consistent with the data
from which the values were generated (cf. Martin de Llano
and Manning (33), Fig. 8, and Himanen et al. (34), Fig. 6).
This demonstrates the power of the present method, since a
single dextran measurement suffices to ascertain the solu-
bility with significantly greater precision. Especially impor-
tant for future work will be the degree to which various
mutations do not show additive free energies (e.g., the effects
of L88A and K95I, comparing their separate and joint ener-
gies), indicating some effective interactions between the
mutations’ effects on polymerization.
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